Cytokinetics, Inc. Stock Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Apr. 09 | Cytokinetics Insider Sold Shares Worth $2,422,918, According to a Recent SEC Filing | MT |
Apr. 05 | Sector Update: Health Care Stocks Rise Friday Afternoon | MT |
Financials (USD)
Sales 2024 * | 12.11M | Sales 2025 * | 165M | Capitalization | 6.87B |
---|---|---|---|---|---|
Net income 2024 * | -466M | Net income 2025 * | -353M | EV / Sales 2024 * | 545 x |
Net cash position 2024 * | 276M | Net cash position 2025 * | 606M | EV / Sales 2025 * | 38 x |
P/E ratio 2024 * |
-14.9
x | P/E ratio 2025 * |
-20.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 98-06-30 |
Kari Loeser
CMP | Compliance Officer | - | 21-10-31 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 19-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20-11-19 |
Edward Kaye
BRD | Director/Board Member | 75 | 16-05-19 |
Santo Costa
BRD | Director/Board Member | 78 | 10-09-30 |
1st Jan change | Capi. | |
---|---|---|
-0.49% | 105B | |
+3.31% | 97.5B | |
+3.17% | 22.19B | |
-16.16% | 21.33B | |
-7.05% | 18.68B | |
-41.41% | 16.6B | |
-22.87% | 14.52B | |
+6.32% | 14.09B | |
+21.46% | 10.99B |